Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)



Status:Recruiting
Conditions:Cervical Cancer, Cervical Cancer, Cancer, Women's Studies
Therapuetic Areas:Oncology, Reproductive
Healthy:No
Age Range:18 - Any
Updated:3/29/2019
Start Date:October 25, 2018
End Date:November 23, 2022
Contact:Toll Free Number
Email:Trialsites@merck.com
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475)
plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of
placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women
with persistent, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens
include: paclitaxel plus cisplatin with or without bevacizumab and paclitaxel plus
carboplatin with or without bevacizumab.

The primary study hypotheses are that the combination of pembrolizumab plus chemotherapy is
superior to placebo plus chemotherapy with respect to: 1) Progression-free Survival (PFS) per
Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by blinded independent
central review (BICR), or, 2) Overall Survival (OS).


Inclusion Criteria:

- Has persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous
carcinoma, or adenocarcinoma of the cervix which has not been treated with systemic
chemotherapy and is not amenable to curative treatment (such as with surgery and/or
radiation)

- Not pregnant or breastfeeding, and at least one of the following conditions applies:
a.) Not a woman of childbearing potential (WOCBP), b.) A WOCBP must agree to use
effective contraception during the treatment period and for at least 120 days after
the last dose of pembrolizumab/placebo or 210 days after the last dose of chemotherapy

- Has measurable disease per RECIST 1.1 as assessed by the local site
investigator/radiology

- Has provided archival tumor tissue sample or newly obtained core or excisional biopsy
of a tumor lesion not previously irradiated for prospective determination of
Programmed Cell Death-Ligand 1 (PD-L1) status prior to randomization

- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within
14 days prior to randomization

- Has adequate organ function

Exclusion Criteria:

- A WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization

- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Participants with known brain metastases may participate provided that the
brain metastases have been previously treated (except with chemotherapy) and are
radiographically stable.

- Has a known additional malignancy that is progressing or has required active treatment
within the past 3 years. Note: Participants with basal cell carcinoma of the skin,
squamous cell carcinoma of the skin, transitional cell carcinoma of urothelial cancer,
or carcinoma in situ (e.g. breast cancer) that have undergone potentially curative
therapy are not excluded.

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in doses exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to randomization

- Has an active autoimmune disease that has required systemic treatment in past 2 years
(i.e., with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency) is not considered a form
of systemic treatment and is allowed

- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis

- Has an active infection requiring systemic therapy

- Has a known history of human immunodeficiency virus (HIV) infection

- Has a known history of Hepatitis B or known active Hepatitis C virus infection

- Has a known history of active tuberculosis (TB; Bacillus tuberculosis)

- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g.
cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40, CD137)

- Has received prior systemic chemotherapy for treatment of cervical cancer.

- Has not recovered adequately from toxicity and/or complications from surgery prior to
randomization

- Has received prior radiotherapy within 2 weeks prior to randomization. Participants
must have recovered from all radiation-related toxicities, not require
corticosteroids, and not have had radiation pneumonitis.

- Has received a live vaccine within 30 days prior to randomization

- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.

- Has a contraindication or hypersensitivity to any component of cisplatin, carboplatin,
paclitaxel, or bevacizumab

- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to randomization

- Is pregnant or breastfeeding or expecting to conceive within the projected duration of
the study, starting with the screening visit through 120 days following last dose of
pembrolizumab/placebo and 210 days following last dose of chemotherapy

- Has had an allogeneic tissue/solid organ transplant
We found this trial at
17
sites
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Phone: 813-745-3593
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
4100 John R
Detroit, Michigan 48201
800-527-6266
Phone: 313-576-8994
Barbara Ann Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Phone: 206-543-3669
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Phone: 907-212-4732
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Augusta, Georgia 30912
Phone: 706-721-3473
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Berazategui, Buenos Aires
Phone: +541142262013
?
mi
from
Berazategui,
Click here to add this to my saved trials
Detroit, Michigan 48202
Phone: 313-916-3590
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Germantown, Tennessee 38138
Phone: 901-683-0055
?
mi
from
Germantown, TN
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Phone: 212-342-6895
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Newark, New Jersey 07103
Phone: 973-972-5266
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Phone: 405-271-8777
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orange, California
Phone: 877-827-8839
?
mi
from
Orange, CA
Click here to add this to my saved trials
Phoenix, Arizona 85016
Phone: 281-863-4567
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Phone: 314-362-1760
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Antonio, Texas 78229
Phone: 281-863-4567
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Teaneck, New Jersey 07666
Phone: 201-227-6200
?
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Tulsa, Oklahoma 74146
Phone: 91850532014075
?
mi
from
Tulsa, OK
Click here to add this to my saved trials